Skip to main content
Premium Trial:

Request an Annual Quote

Complete Genomics Reports $4.2M in Third-Quarter Revenue

Premium

This article has been updated to correct the operating expenses for the third quarter of 2009.

As it is preparing for its initial public offering, Complete Genomics this week reported $4.2 million in revenue for the third quarter, along with a net loss of $20.5 million.

The company had no revenue during the third quarter of 2009, and a $9.25 million net loss.

As previously stated, Complete Genomics had $9 million worth of backlog orders as of Sept. 30, for which it expects to bill customers within the next 12 months.

The company had operating expenses of $14.9 million during the quarter, up from $8.6 million during the year-ago quarter. As of Sept. 30, it had $10.5 million in cash and cash equivalents.

Last month, Complete Genomics raised its maximum aggregate offering price for its planned IPO to $96.6 million, from an earlier target of $86.25 million (IS 10/26/2010).

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.